PT  - JOURNAL ARTICLE
AU  - Boltz, Kathy
ED  - Shen, Guoxiang
TI  - The PAOLA Study
DP  - 2015 Jun 18
TA  - MD Conference Express
PG  - 8--10
VI  - 15
IP  - 4
4099  - http://mdc.sagepub.com/content/15/4/8.2.short
4100  - http://mdc.sagepub.com/content/15/4/8.2.full
AB  - Pasireotide LAR had a dose-proportional relationship with dose exposure over a 40- to 60-mg range. Efficacy end points of levels of growth hormone and IGF-1 were correlated with pasireotide exposure, and response rates were higher at the higher pasireotide dose.